Fairmount Funds Management LLC Cogent Biosciences, Inc. Transaction History
Fairmount Funds Management LLC
- $326 Million
- Q2 2025
A detailed history of Fairmount Funds Management LLC transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Fairmount Funds Management LLC holds 6,225,641 shares of COGT stock, worth $71.9 Million. This represents 13.7% of its overall portfolio holdings.
Number of Shares
6,225,641
Previous 6,225,641
-0.0%
Holding current value
$71.9 Million
Previous $37.3 Million
19.87%
% of portfolio
13.7%
Previous 12.7%
Shares
5 transactions
Others Institutions Holding COGT
# of Institutions
203Shares Held
117MCall Options Held
2.84MPut Options Held
828K-
Paradigm Biocapital Advisors LP New York, NY10.4MShares$120 Million3.47% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.49MShares$98.1 Million7.28% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$84.2 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.96MShares$80.4 Million10.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.52MShares$75.3 Million0.0% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $760M
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...